Phase 1/2a Clinical Trial of T3011, an Oncolytic HSV Delivering IL-12 and PD-1 Antibody, Administered Intratumorally as a Monotherapy for Advanced Solid Tumors, Including Recurrent or Metastatic HNSCC - Poll - DentalSpire

Phase 1/2a Clinical Trial of T3011, an Oncolytic HSV Delivering IL-12 and PD-1 Antibody, Administered Intratumorally as a Monotherapy for Advanced Solid Tumors, Including Recurrent or Metastatic HNSCC

  • By

  • Dongmei Ji

  • Wenmin Fu

  • Yonghong Liu

  • Weina Shen

  • Muyu Kuang

  • Zhouyu Ning

  • Youzhou Sang

  • Guangliang Chen

  • Jian Zhang

  • Zijie Zhou

  • Dashuang Xu

  • Xu Jin

  • Junlong Wu

  • Xusha Zhou

  • Jing Zhao

  • Lei Wang

  • Yukun Liu

  • Xi Zhang

  • Runbin Yan

  • Xiaoqing Chen

  • Grace Zhou

  • Jiaxin Niu

  • Xichun Hu

  • February 20, 2026

  • 0 min

Share

Original Source(s)

Phase 1/2a Clinical Trial of T3011, an Oncolytic HSV Delivering IL-12 and PD-1 Antibody, Administered Intratumorally as a Monotherapy for Advanced Solid Tumors, Including Recurrent or Metastatic HNSCC

  • by Dongmei Ji, Wenmin Fu, Yonghong Liu, Weina Shen, Muyu Kuang, Zhouyu Ning, Youzhou Sang, Guangliang Chen, Jian Zhang, Zijie Zhou, Dashuang Xu, Xu Jin, Junlong Wu, Xusha Zhou, Jing Zhao, Lei Wang, Yukun Liu, Xi Zhang, Runbin Yan, Xiaoqing Chen, Grace Zhou, Jiaxin Niu, Xichun Hu

  • February 20, 2026

Related Content

Medical Oddities: Chew on This Cancer Prevention Idea

From gum to gut to memory—medicine gets weirdly clever fast 

Grill Brush Bristle Injuries Continue to Rise

Most patients were treated and released, with the oropharynx the most common injury site

One Day Jaw Reconstruction

Jaw surgery for cancer patients and others can sometimes take several years to be completed, with the patient undergoing multiple procedures to place a prosthetic, secure and attach dental implants and undergo treatment for their disease.

  • June 26, 2023

  • 3 min